Mrs. Bindi Chudgar stands as a distinguished figure in the corporate world, spearheading Lambda Therapeutic Research since its inception. Her entrepreneurial acumen has been pivotal in steering Lambda’s growth, both organically and inorganically, propelling it into a truly global Clinical Research Organization (CRO). With a progressive vision and unwavering values, Mrs. Chudgar has carved out a unique niche for Lambda, setting it apart in the competitive landscape of the CRO industry.

Meticulous by nature, Mrs. Chudgar oversees Lambda & Novum’s Corporate M&A, Strategy, Finance, and Human Resources. Her approach blends contemporary and conventional ideologies, tailored to be the best fit for the organization on a global scale.

Mrs. Chudgar’s commitment to high-quality standards is exemplified in Lambda’s exceptional regulatory track record. The organization’s facilities worldwide have successfully earned accreditations from some of the world’s top regulatory agencies. Her visionary genius and strong-willed determination enable Lambda to transcend geographical boundaries, excelling in the world’s most promising pharmaceutical markets while continually expanding and diversifying its service portfolio and expertise.

A true advocate for people-centric leadership, Mrs. Chudgar is dedicated to fostering an engaging and empowering work culture. She recognizes that these elements form the foundation and key drivers for building a robust and successful organization.

Driven by an unwavering determination, Mrs. Chudgar aims to continually raise the bar for the development and commercialization of new medical therapies worldwide through Lambda & Novum.